Investors Capital Advisory Services’s Ligand Pharmaceuticals LGND Stock Holding History

Investors Capital Advisory Services’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,256	Closed	-$204K	–	748
2015 Q2	$204K	Buy	+3,256	New	+$178K	0.04%	610

Other funds holding LGND

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Investors Capital Advisory Services's LGND Position: Q3 2015 in Review

Investors Capital Advisory Services sold out of Ligand Pharmaceuticals (LGND) in Q3 2015, closing a stake of 3,256 shares — an estimated $204K sold.

Investors Capital Advisory Services first reported a position in LGND in Q2 2015 and held it in 1 quarter. The position peaked at $204K in Q2 2015. 203 funds tracked by Wall St. Rank hold LGND as of Q3 2015.

Investors Capital Advisory Services reported no remaining Ligand Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Investors Capital Advisory Services sold 3,256 Ligand Pharmaceuticals shares in Q3 2015, an estimated $204K.
Investors Capital Advisory Services first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 1 quarter.
Investors Capital Advisory Services's Ligand Pharmaceuticals position peaked at $204K in Q2 2015.
203 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2015.

Based on Investors Capital Advisory Services's 13F filing for Q3 2015, filed 17 Nov 2015.